Black Diamond Therapeutics Announces Phase 2 Silevertinib Clinical Trial Results
Black Diamond Therapeutics will host a webcast on December 3, 2025, to present Phase 2 clinical trial results of silevertinib, a fourth-generation EGFR inhibitor for EGFR-mutant NSCLC and glioblastoma. The webcast details are available on their website.
Black Diamond Therapeutics Inc. announced that it will host a webcast presentation to highlight results from its Phase 2 clinical trial of silevertinib and provide a program update. The webcast is scheduled for Wednesday, December 3, 2025, at 8:00am ET. Results from the Phase 2 clinical trial will be presented during this event. Silevertinib is a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor being evaluated in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma. Further information and access to the webcast will be available on the Investors section of the Black Diamond Therapeutics website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594425-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
